Harmony Biosciences CEO and leadership

Mr. Jacobs is President and Chief Executive Officer for Harmony Biosciences.

He joined Harmony from Teva Pharmaceuticals, where he held leadership roles as Senior Vice President and General Manager of the Respiratory Business Unit, Senior Vice President of Commercial Operations in North America and General Manager of Teva in Canada. Prior to joining Teva, he held positions of increasing scope and responsibility at major pharmaceutical companies, including Cephalon, Wyeth and Pfizer. Mr. Jacobs has over 25 years of commercial experience across multiple therapeutic areas, including CNS, Sleep Disorders, Pain Care and Respiratory, as well as rare disease and other specialty markets. His demonstrated expertise in developing market-leading commercial strategies, major product launches and building and leading highly effective teams and organizations has helped to shape Harmony’s positive culture of compassion for patients and passion for the business.

He holds a bachelor’s degree in business and a Master of Business Administration in marketing from the State University of New York.

Jeffrey M. Dayno, M.D., is Chief Medical Officer for Harmony Biosciences. A nationally recognized expert in neuroscience, Dr. Dayno is currently responsible for managing research, development and medical and regulatory affairs for Harmony Biosciences.

He is a neurologist with 10 years experience in clinical/academic medicine followed by over 20 years experience in leadership roles at Merck & Co., Cephalon, and ViroPharma, building and leading clinical, regulatory and medical affairs teams toward multiple NDA approvals and medical support of successful product launches.

Dr. Dayno has served as Principal Investigator on numerous clinical trials and published and lectured extensively on various topics in the field of Neurology, with a focus on stroke, sleep disorders, pain and migraine. He has also served as a peer reviewer for several scientific neurology journals.

Dr. Dayno earned his medical degree from Temple University School of Medicine, did his residency training in Neurology at Temple University Hospital, and completed a fellowship in Stroke and Cerebrovascular Disorders in the Department of Neurology at Henry Ford Hospital.

Mr. Serafin is the Chief Strategy Officer at Harmony Biosciences and is responsible for leading the company’s corporate strategy, business and corporate development initiatives, and alliance management efforts, including the expansion of the company’s pipeline through the acquisition and licensing of novel rare disease therapies for patients with high, unmet needs.

Mr. Serafin has 20 years of experience in mergers and acquisitions and corporate legal counseling in the pharmaceutical, broader healthcare, and technology sectors. Mr. Serafin previously served as Vice President of Business Development at Marathon Pharmaceuticals, LLC, Vice President of M&A and General Counsel at AltaThera Pharmaceuticals, and Vice President of U.S. Legal Affairs and Associate General Counsel at Lundbeck Inc., where he oversaw and executed on transactions with valuations of up to $1 billion.

Mr. Serafin began his career in private legal practice, where he specialized in corporate transactions, provided strategic legal and business consulting advice to clients, and consummated both public and private deals, including acquisitions, divestitures, and collaborations.

He holds a Bachelor of Science degree from the University of Illinois, a Juris Doctor from the Loyola University Chicago School of Law, and a Masters of Business Administration from the Northwestern University Kellogg School of Management.

Sandip Kapadia has served as the Chief Financial Officer and Treasurer since July 2016. Mr. Kapadia has over 20 years of experience in building and leading finance and administration teams at life sciences companies both in the United States and abroad. Prior to joining Intercept, Mr. Kapadia held finance leadership positions over 19 years at Novartis and Novartis affiliates in the United States, Switzerland, the Netherlands and the United Kingdom, including most recently Chief Financial Officer of North America at Novartis’s generic division, Sandoz. Mr. Kapadia has been a director of Passage Bio since January 2020 and Molecular Partners AG since April 2020, and previously was a director of Therachon AG. Mr. Kapadia earned his bachelor’s degree in business administration and accounting from Montclair State University, an M.B.A from Rutgers Graduate School of Management and is a certified public accountant.

Mr. Jacobs is President and Chief Executive Officer for Harmony Biosciences.

He joined Harmony from Teva Pharmaceuticals, where he held leadership roles as Senior Vice President and General Manager of the Respiratory Business Unit, Senior Vice President of Commercial Operations in North America and General Manager of Teva in Canada. Prior to joining Teva, he held positions of increasing scope and responsibility at major pharmaceutical companies, including Cephalon, Wyeth and Pfizer. Mr. Jacobs has over 25 years of commercial experience across multiple therapeutic areas, including CNS, Sleep Disorders, Pain Care and Respiratory, as well as rare disease and other specialty markets. His demonstrated expertise in developing market-leading commercial strategies, major product launches and building and leading highly effective teams and organizations has helped to shape Harmony’s positive culture of compassion for patients and passion for the business.

He holds a bachelor’s degree in business and a Master of Business Administration in marketing from the State University of New York.

Jeffrey M. Dayno, M.D., is Chief Medical Officer for Harmony Biosciences. A nationally recognized expert in neuroscience, Dr. Dayno is currently responsible for managing research, development and medical and regulatory affairs for Harmony Biosciences.

He is a neurologist with 10 years experience in clinical/academic medicine followed by over 20 years experience in leadership roles at Merck & Co., Cephalon, and ViroPharma, building and leading clinical, regulatory and medical affairs teams toward multiple NDA approvals and medical support of successful product launches.

Dr. Dayno has served as Principal Investigator on numerous clinical trials and published and lectured extensively on various topics in the field of Neurology, with a focus on stroke, sleep disorders, pain and migraine. He has also served as a peer reviewer for several scientific neurology journals.

Dr. Dayno earned his medical degree from Temple University School of Medicine, did his residency training in Neurology at Temple University Hospital, and completed a fellowship in Stroke and Cerebrovascular Disorders in the Department of Neurology at Henry Ford Hospital.

Mr. Serafin is the Chief Strategy Officer at Harmony Biosciences and is responsible for leading the company’s corporate strategy, business and corporate development initiatives, and alliance management efforts, including the expansion of the company’s pipeline through the acquisition and licensing of novel rare disease therapies for patients with high, unmet needs.

Mr. Serafin has 20 years of experience in mergers and acquisitions and corporate legal counseling in the pharmaceutical, broader healthcare, and technology sectors. Mr. Serafin previously served as Vice President of Business Development at Marathon Pharmaceuticals, LLC, Vice President of M&A and General Counsel at AltaThera Pharmaceuticals, and Vice President of U.S. Legal Affairs and Associate General Counsel at Lundbeck Inc., where he oversaw and executed on transactions with valuations of up to $1 billion.

Mr. Serafin began his career in private legal practice, where he specialized in corporate transactions, provided strategic legal and business consulting advice to clients, and consummated both public and private deals, including acquisitions, divestitures, and collaborations.

He holds a Bachelor of Science degree from the University of Illinois, a Juris Doctor from the Loyola University Chicago School of Law, and a Masters of Business Administration from the Northwestern University Kellogg School of Management.

Sandip Kapadia has served as the Chief Financial Officer and Treasurer since July 2016. Mr. Kapadia has over 20 years of experience in building and leading finance and administration teams at life sciences companies both in the United States and abroad. Prior to joining Intercept, Mr. Kapadia held finance leadership positions over 19 years at Novartis and Novartis affiliates in the United States, Switzerland, the Netherlands and the United Kingdom, including most recently Chief Financial Officer of North America at Novartis’s generic division, Sandoz. Mr. Kapadia has been a director of Passage Bio since January 2020 and Molecular Partners AG since April 2020, and previously was a director of Therachon AG. Mr. Kapadia earned his bachelor’s degree in business administration and accounting from Montclair State University, an M.B.A from Rutgers Graduate School of Management and is a certified public accountant.

Mr. Jacobs is President and Chief Executive Officer for Harmony Biosciences.

He joined Harmony from Teva Pharmaceuticals, where he held leadership roles as Senior Vice President and General Manager of the Respiratory Business Unit, Senior Vice President of Commercial Operations in North America and General Manager of Teva in Canada. Prior to joining Teva, he held positions of increasing scope and responsibility at major pharmaceutical companies, including Cephalon, Wyeth and Pfizer. Mr. Jacobs has over 25 years of commercial experience across multiple therapeutic areas, including CNS, Sleep Disorders, Pain Care and Respiratory, as well as rare disease and other specialty markets. His demonstrated expertise in developing market-leading commercial strategies, major product launches and building and leading highly effective teams and organizations has helped to shape Harmony’s positive culture of compassion for patients and passion for the business.

He holds a bachelor’s degree in business and a Master of Business Administration in marketing from the State University of New York.